GLPwatch
Papers (12034)
Page 101 of 201, ranked by citation count.
- Liraglutide Exerts Potential Anti-inflammatory Effect in Type 1 Diabetes by Inhibiting IFN-γ Production <i>via</i> Suppressing JAK-STAT Pathway.
- Semaglutide normalizes increased cardiomyocyte calcium transients in a rat model of high fat diet-induced obesity.
- Efficacy of metformin combined with liraglutide on the glucose and lipid metabolism, vascular endothelial function, and oxidative stress of patients with T2DM and metabolic syndrome.
- Incidence of adhesions in patients using liraglutide before laparoscopic sleeve gastrectomy.
- Real-world effectiveness of liraglutide versus dulaglutide in Japanese patients with type 2 diabetes: a retrospective study.
- Semaglutide Versus Other Glucagon-Like Peptide-1 Agonists for Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis.
- Semaglutide: should the media slim down its enthusiasm?
- Islet Autoimmunity in Adults With Impaired Glucose Tolerance and Recently Diagnosed, Treatment Naïve Type 2 Diabetes in the Restoring Insulin SEcretion (RISE) Study.
- On demand regulation of blood glucose level by biocompatible oxidized starch-Con A nanogels for glucose-responsive release of exenatide.
- Novel insights into the augmented effect of curcumin and liraglutide in ameliorating cisplatin-induced nephrotoxicity in rats: Effects on oxidative stress, inflammation, apoptosis and pyroptosis via GSK-3β.
- Amyloidogenicity of peptides targeting diabetes and obesity.
- Transitioning from basal-bolus or premix insulin therapy to a combination of basal insulin and glucagon-like peptide-1 receptor agonist in people with type 2 diabetes.
- Cost-Effectiveness of iGlarLixi in People with Type 2 Diabetes Mellitus Suboptimally Controlled on Basal Insulin Plus Metformin in the UK.
- Type 2 diabetes and cardiovascular prevention: the dogmas disputed.
- Tirzepatide for Congenital Generalized Lipodystrophy.
- Switching from sitagliptin to liraglutide to manage patients with type 2 diabetes in the UK: A long-term cost-effectiveness analysis.
- Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes.
- Brain Activation in Response to Low-Calorie Food Pictures: An Explorative Analysis of a Randomized Trial With Dapagliflozin and Exenatide.
- Pyoderma gangrenosum associated with dulaglutide therapy.
- Lilly's tirzepatide secures first approval in diabetes, paving path for dual-acting hormone mimetics.
- Efficacy and Safety of Glucagon-Like Peptide-1 Receptor Agonists for Obesity Management in Adults With and Without Type 2 Diabetes: A Systematic Review.
- Liraglutide Effect on Ventricular Transient Outward K + Channel and Connexin-43 Protein Expression.
- Regional gastrointestinal pH profile is altered in patients with type 1 diabetes and peripheral neuropathy.
- Impact on glycated haemoglobin and body weight changes after stopping tirzepatide for 4 weeks in the SURPASS-1 monotherapy trial.
- Use of iGlarLixi for Management of Type 2 Diabetes in Japanese Clinical Practice: SPARTA Japan, a Retrospective Observational Study.
- Glucagon-Like Peptide-1 Receptor-Targeted PET/CT With 68 Ga-HBED-CC-Exendin-4 in Localizing Insulinoma : A Head-to-Head Comparison to 68 Ga-NOTA-Exendin-4.
- Semaglutide administration protects cardiomyocytes in db/db mice via energetic improvement and mitochondrial quality control.
- Effects of E2HSA, a Long-Acting Glucagon Like Peptide-1 Receptor Agonist, on Glycemic Control and Beta Cell Function in Spontaneous Diabetic db/db Mice.
- Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes.
- Notch signaling is involved in the antiapoptotic effects of liraglutide on rat H9c2 cardiomyocytes exposed to hypoxia followed by reoxygenation.
- The novel use of GLP-1 analogue and insulin combination in type 2 diabetes mellitus.
- Comparative effectiveness of tirzepatide versus bariatric metabolic surgery in adults with metabolic-associated steatotic liver disease and obesity: a multi-institutional propensity score-matched study.
- A Probable Case of Tirzepatide-Induced Acute Pancreatitis.
- Semaglutide as an Adjunctive Therapy to Standard Management for Idiopathic Intracranial Hypertension: A Real-World Data-Based Retrospective Analysis.
- Liraglutide Attenuates Aortic Valve Calcification in a High-Cholesterol-Diet-Induced Experimental Calcific Aortic Valve Disease Model in Apolipoprotein E-Deficient Mice.
- Exendin-4 Plays a Protective Role in a Rat Model of Spinal Cord Injury Through SERCA2.
- Estimating the real world daily usage and cost for exenatide twice daily and liraglutide in Germany, the Netherlands, and the UK based on volumes dispensed by pharmacies.
- A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes.
- Current treatments and strategies for type 2 diabetes: can we do better with GLP-1 receptor agonists?
- Cardioprotective properties of glucagon-like peptide-1 receptor agonists in type 2 diabetes mellitus patients: A systematic review.
- Semaglutide Pretreatment Induces Cardiac Autophagy to Reduce Myocardial Injury in Septic Mice.
- Hypophagia and body weight loss by tirzepatide are accompanied by fewer GI adverse events compared to semaglutide in preclinical models.
- Cardioprotective Actions of a Glucagon-like Peptide-1 Receptor Agonist on Hearts Donated After Circulatory Death.
- Tirzepatide: A New Generation Therapeutic for Diabetes Type 2.
- Phosphorylated proteomics-based analysis of the effects of semaglutide on hippocampi of high-fat diet-induced-obese mice.
- Glucagon-like peptide-1 reduces pancreatic β-cell mass through hypothalamic neural pathways in high-fat diet-induced obese rats.
- Noninvasive evaluation of donor and native pancreases following simultaneous pancreas-kidney transplantation using positron emission tomography/computed tomography.
- Effect of Liraglutide on Cardiometabolic Risk Profile in People with Coronary Artery Disease with or without Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
- Semaglutide, a Long-Acting GLP-1 Analogue, for the Management of Early-Onset Obesity due to MC4R Defect: A Case Report.
- Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction.
- A novel protective modality against rotenone-induced Parkinson's disease: A pre-clinical study with dulaglutide.
- Semaglutide is effective in type 2 diabetes and obesity with schizophrenia.
- Combined Probe Strategy to Increase the Enzymatic Digestion Rate and Accelerate the Renal Radioactivity Clearance of Peptide Radiotracers.
- Glucagon-Like Peptide 1 Receptor Agonist Stimulation Inhibits Laser-Induced Choroidal Neovascularization by Suppressing Intraocular Inflammation.
- Comparing the use of individual and composite terms to evaluate adverse drug event disproportionality: a focus on glucagon-like peptide-1 receptor agonists and diabetic retinopathy.
- Japan initiates market authorization of weight-loss drug semaglutide under universal health coverage, but with stringent prescription restrictions.
- The role of basal insulin and GLP-1 receptor agonist combination products in the management of type 2 diabetes.
- Albumin-binding DARPins as scaffold improve the hypoglycemic and anti-obesity effects of exendin-4 in vivo.
- Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
- Cardiovascular outcomes and healthcare costs of liraglutide versus basal insulin for type 2 diabetes patients at high cardiovascular risk.